If you’ve spent time in recovery circles or sat through a laser rep’s seminar, you’ve probably heard a version of this: red light is for muscles and joints, green is for “neurological” benefits, and a gentle Class 2 laser is actually more effective than a powerful Class 4. It’s a clean, confident story. It’s also three separate claims — one about wavelength, one about laser class, one about dose — braided into a single pitch. Each sits on very different evidence, and pulling them apart is the whole point of this article.
We’ll give credit where it’s earned: cold laser is real photobiomodulation, and some of it has legitimate research behind it. But “has evidence for X” and “does everything the seminar claims” are miles apart — and that gap is exactly where marketing lives. Here’s the honest version.
First, the Common Ground: It’s All Photobiomodulation
Cold laser, low-level laser therapy (LLLT), and the red light panels you’ve seen are all forms of the same thing: photobiomodulation (PBM). Specific wavelengths of light are absorbed by an enzyme in your mitochondria — cytochrome c oxidase — which nudges cellular energy production, oxidative stress, and inflammatory signaling.[1] We covered the mechanism in depth in our red light vs. Class IV laser breakdown, so we won’t relitigate it here.
What matters for the seminar’s claims is this: once you accept that it’s all PBM, the real questions become narrow and physical. What wavelength? What dose? Delivered to what depth? Every claim about red versus green, or Class 2 versus Class 4, is really a claim about one of those three variables. So let’s take them one at a time.
Red vs. Green: Two Different Jobs, Two Different Evidence Bases
The “red for muscles, green for the brain” framing makes it sound like the two colors are interchangeable tools for different rooms in the same house. They aren’t. They behave differently in tissue, and the research behind them is not remotely equal.
Red & Near-Infrared (635–850 nm)
The musculoskeletal workhorse
- Penetrates progressively deeper — NIR reaches muscle, tendon, joint
- Well-absorbed by cytochrome c oxidase; increases cellular ATP
- The wavelength range behind most credible PBM research
- Independent meta-analyses support it for some MSK pain
Green (520–540 nm)
Shallow, and biologically different
- Strongly absorbed at the surface — minimal depth of penetration
- In lab cell studies, can reduce ATP and cell proliferation
- Used commercially for body contouring (fat-cell disruption)
- Direct musculoskeletal outcome evidence is thin
Shorter wavelengths scatter and get absorbed faster. Green light (around 520 nm) is largely absorbed in the first fractions of a millimeter of tissue, so very little reaches deep structures.[2] And the cellular effect isn’t just “weaker red” — it can be opposite. A Harvard-affiliated laboratory study found that red and near-infrared light increased ATP and stimulated cell proliferation, while green and blue light reduced ATP and inhibited proliferation.[3] That inhibitory effect is a plausible reason green diode lasers are marketed for fat-cell and body-contouring use — a very different goal than stimulating tissue repair.
Sources: Tissue light-transport modeling of visible/NIR wavelengths; Wang, Huang, Hamblin et al., Scientific Reports 2017 (wavelength-dependent ATP and proliferation effects).Green light barely reaches the muscle under your skin.
The claim that it reaches your brain is a different story entirely.
The Green “Neurological” Claim — Where It Comes From, and Where It Breaks
This is the claim worth slowing down on, because it’s the one most likely to mislead. There is real, interesting research on green light and the nervous system — but it describes something almost entirely unlike a green laser pressed against your body.
The credible green-light neurological research — led by Harvard’s Rami Burstein and by Mohab Ibrahim at the University of Arizona — uses green light delivered through the eyes: LED lamps or filtered glasses, viewed for one to two hours a day over weeks, to reduce migraine frequency and photophobia.[4] The proposed mechanism is the visual pathway — the retina signaling the brain’s pain-modulating systems — not light physically penetrating to neural tissue. It’s promising, but still early and pilot-stage, with mixed results across trials. A green laser applied to your neck or a joint engages none of that machinery. Borrowing eye-delivered migraine findings to sell a tissue laser for “neurological benefits” braids two unrelated mechanisms into one marketing claim.
To be fair to the science: green light, viewed through the eyes, may genuinely help some migraine and photophobia patients, and that’s a legitimate research avenue worth watching. What it is not is evidence that a green cold laser on your body does anything neurological. Same color, different universe.
Class 2 vs. Class 4: A Safety Rating, Not a Report Card
The second big seminar claim is that a lower-class laser is gentler and, somehow, more effective than a high-powered one. This one contains a real kernel of truth wrapped in a category error.
Start with what “class” actually means. Laser class is a safety classification — it describes the hazard a device poses to your eyes and skin based on power output, nothing more. Class 2 is low-power; Class 3R and 3B are moderate; Class 4 is high-power and requires eye protection and a trained operator. The class label tells you how careful to be. It says nothing directly about clinical effectiveness.
Here’s the legitimate kernel. Photobiomodulation follows a biphasic dose response — often called the Arndt-Schulz curve. Low doses of light stimulate tissue; moderate doses can do nothing; and high doses can actually inhibit or suppress the very response you wanted.[5] So “more power is not always better” is genuinely true — there’s a therapeutic window, and blasting past it can reduce or reverse the benefit. That’s the valid point buried inside the Class 2 pitch.
But notice what the dose-response curve is actually about: the dose delivered to the target tissue — not the class stamped on the housing. A low-power Class 2 laser is well-suited to superficial or dose-sensitive targets, where a gentle dose lands right in the sweet spot. But for a deep joint, that same low output may deliver a sub-threshold dose — too few photons reaching depth to trigger a meaningful response. “Gentle” is a question of matching the dose to the target, not a universal virtue. Class 4’s higher power is genuinely useful when you need to push an adequate dose to something deep, quickly. Neither class is inherently “better”; they’re suited to different jobs.
Low-power lasers produce no heat and no sensation — which means what a patient feels during treatment is completely disconnected from the dose actually delivered. That’s worth remembering when “patients perceive a strong effect” is offered as evidence. A therapy you can’t feel is exactly the kind most vulnerable to placebo response. Tellingly, the placebo (sham) lasers used in cold-laser trials are designed to look identical to the real device and even emit visible light, precisely because neither patient nor clinician can otherwise tell them apart.[6]
“FDA-Cleared” — What It Does and Doesn’t Mean
Much of the seminar’s authority rests on FDA clearance, and here we’ll give real credit: the manufacturer most associated with these claims, Erchonia, has invested more in clinical research than most of the field, holding roughly 17 FDA 510(k) clearances backed by their own randomized, placebo-controlled trials.[6] That’s a meaningfully higher bar than the many devices marketed as “FDA cleared” on paperwork alone. Credit where it’s due.
A 510(k) clearance authorizes a device for a specific, narrow indication — for these lasers, things like temporary relief of chronic neck and shoulder pain, chronic heel pain from plantar fasciitis, post-surgical pain at 24 hours, or body-circumference reduction.[6] It does not certify the device as effective for everything discussed in a seminar. Two honest limitations sit alongside the credit: most of the pivotal trials are manufacturer-sponsored single studies using subjective pain scales, and independent replication is thinner than the marketing implies — an orthopedic review noted the broader literature offers limited direction on efficacy.[6]
So “FDA cleared” is a real signal — but it’s a signal about a specific use, tested a specific way. It is not a blanket stamp that validates the color-coded, class-coded claims layered on top of it.
So What Actually Holds Up?
Strip away the seminar framing and a genuinely useful picture remains — because cold laser is not snake oil. Independent, non-manufacturer research supports red and near-infrared PBM for several conditions, at the right dose.
| The claim / use | What the independent evidence says |
|---|---|
| Red/NIR laser for neck pain | Supported — a Lancet meta-analysis found reduced pain, acute and chronic |
| Red/NIR laser for tendinopathy (elbow, shoulder, Achilles) | Promising but dose-dependent and mixed — benefit clusters at correct doses |
| Red/NIR laser for knee osteoarthritis | Modest support in several trials, as an adjunct |
| Green laser for musculoskeletal injury | Minimal direct outcome evidence |
| Green light (eye-delivered) for migraine | Early, pilot-stage, promising but unproven |
| Class 2 inherently better than Class 4 | Not established — it’s the dose at the target, not the class label |
| Cold laser as a standalone cure | No — it’s an adjunct in every credible study |
Evidence reflects independent (non-manufacturer) systematic reviews and trials where available. Red/NIR wavelengths carry the bulk of the musculoskeletal support; certainty of evidence across the field is often low, and dosing quality varies widely between studies.
How to Pressure-Test Any Laser Claim
You don’t need a physics degree to sort signal from sales. Run any cold-laser pitch through three questions:
-
What wavelength — and does it match the target depth?
Red and NIR for tissue and joints; green is shallow and biologically different. “Green for your brain” from a body-applied laser is a red flag.
-
What’s the dose at the target — not the class on the label?
Class is a safety rating. The biphasic dose response means the right dose matters more than raw power or a low-class marketing story.
-
Is the indication independently supported, or a single company trial?
FDA clearance covers a specific use. Ask whether non-manufacturer research backs the specific claim being made to you.
The Lesson That Actually Matters
If you take one thing from this: the color on the marketing sheet and the class on the housing tell you far less than wavelength, dose, and target depth. A well-dosed red or near-infrared treatment aimed at the right tissue can genuinely help. A green laser sold for “neurological” benefits is mixing up mechanisms that have nothing to do with each other. And a low class number is a safety fact, not a performance guarantee.
This connects to the same truth we come back to with every modality: light therapy, at its best, is an adjunct — not the treatment. Photobiomodulation has real but supporting evidence in musculoskeletal care. It works layered onto the things that do the heavy lifting: accurate assessment, hands-on soft-tissue work, and progressive loading. Any clinic building its entire model around a laser — whatever its color or class — has the priorities backwards.
We use light-based therapy where the evidence supports it — red and near-infrared wavelengths, at sensible doses, as one layer of a plan built on assessment, ART, and corrective loading. We won’t sell you a color-coded promise or a class number as if it were a cure, and if your problem genuinely calls for something a laser can’t deliver, we’ll tell you that plainly. That’s the difference between using a tool and marketing one.
The Bottom Line
Red and near-infrared cold laser has legitimate, independently-supported uses in musculoskeletal care — at the right dose, as an adjunct. Green is shallow, biologically different, and its “neurological” story comes from eye-delivered migraine research that has nothing to do with a laser on your body. Laser class is a safety rating, not an effectiveness ranking, even though the biphasic dose response gives the “less can be more” idea a real kernel. And “FDA cleared” certifies a specific use tested a specific way — not the whole seminar.
Don’t choose your care by the color of the diode or the number on the class label. Choose it by whether someone can tell you honestly what any given tool will — and won’t — do for your specific problem.
Wondering If a Modality Is Worth Your Time and Money?
We’ll give you the honest read — what the research supports, what’s marketing, and what will actually move your recovery. Book a visit and we’ll build a plan around what works, not what’s trending.
Book an Assessment ?References
- Review of light parameters and photobiomodulation efficacy. 2021. (Cytochrome c oxidase absorption; ATP; the Arndt-Schulz biphasic dose concept as the foundation of PBM.) PMC
- Tissue light-transport modeling across visible and near-infrared wavelengths. 2022. (480–520 nm light is strongly absorbed near the surface with little deep penetration; red and NIR propagate deeper.) Preprint · penetration thresholds summarized in Huang et al., Dose-Response 2009.
- Wang Y, Huang YY, Wang Y, Lyu P, Hamblin MR. Red (660 nm) or near-infrared (810 nm) photobiomodulation stimulates, while blue (415 nm) and green (540 nm) inhibit, proliferation in human adipose-derived stem cells. Scientific Reports. 2017;7:7781. (Green/blue reduced ATP and proliferation; red/NIR increased both.) PMC
- Green light and the nervous system: Harvard Medical School (Burstein et al.) on narrow-band green light and migraine photophobia; University of Arizona (Ibrahim et al.) green-light pilot studies in migraine and fibromyalgia. (Eye-delivered green light via the visual pathway; early/pilot-stage, mixed across trials.) HMS News
- Huang YY, Sharma SK, Carroll J, Hamblin MR. Biphasic dose response in low level light therapy — an update. Dose-Response. 2011;9(4):602-618. (Low doses stimulate; higher doses can inhibit; the Arndt-Schulz curve in PBM.) PMC
- Erchonia low-level laser FDA 510(k) clearances (neck/shoulder pain, plantar fasciitis, post-surgical pain, body contouring), supported by manufacturer-sponsored placebo-controlled trials; placebo-device design and independent commentary on the evidence base. AAOS Now
- Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis. The Lancet. 2009;374(9705):1897-1908. (Reduced pain in acute neck pain and up to 22 weeks in chronic neck pain.) PubMed
- Bjordal JM, Couppé C, Ljunggren AE, and colleagues. Systematic reviews of LLLT for tendinopathy (lateral elbow, shoulder, Achilles), demonstrating a dose-response pattern; Naterstad et al., BMJ Open 2022 tendinopathy meta-analysis. NCBI
This article is for general educational purposes and does not constitute medical advice. Photobiomodulation is best used as one component of a comprehensive, individualized treatment plan. References to specific manufacturers are for factual context and are not an endorsement or criticism of any company.